New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
06:24 EDTPGNXProgenics upgraded to Buy from Hold at Needham
Needham upgraded Progenics Pharmaceuticals with an $8 price target citing the company's positive Phase 2 data for prostate cancer.
News For PGNX From The Last 14 Days
Check below for free stories on PGNX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 11, 2014
07:06 EDTPGNXSalix, Progenics receive FDA PDUFA date of September 29 for Relistor sNDA
Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the FDA has informed Salix that the supplemental New Drug Application for RELISTOR Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation in patients taking opioids for chronic non-cancer pain has been assigned a user fee goal date of September 29.
August 8, 2014
08:12 EDTPGNXProgenics reports Q2 EPS (17c), consensus (14c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use